Press Releases

Biocon Biologics  /  Press Releases

Biocon Earnings Q4FY20 Revenue Up 6% at Rs 1,644 Cr; EBITDA Down 11% at Rs 382 Cr; Net Profit Down 42% at Rs 123 Cr

  • Posted by: Biocon Biologics

Biocon and Mylan Launch Fulphila®, Biosimilar Pegfilgrastim, in Canada

  • Posted by: Biocon Biologics

Kiran Mazumdar-Shaw Recognized among World’s Top 20 Inspirational Leaders in Biopharmaceuticals in The Medicine Maker ‘Power List 2020’

  • Posted by: Biocon Biologics

Biocon and Mylan Launch Fulphila®, Biosimilar Pegfilgrastim, in Australia

  • Posted by: Biocon Biologics

Biocon & Biocon Biologics Ensuring Manufacturing of Life-Saving Medicines for Patients, Partners and Customers

  • Posted by: Biocon Biologics

Biocon & Mylan Win Patent Litigation Asserted by Sanofi for Insulin Glargine Device Patent in U.S.

  • Posted by: Biocon Biologics

U.S. FDA Accepts Biologics License Application (BLA) for Mylan and Biocon’s Proposed Biosimilar Bevacizumab for Review

  • Posted by: Biocon Biologics

Kiran Mazumdar-Shaw Named EY Entrepreneur of the Year India 2019

  • Posted by: Biocon Biologics

Biocon Q3FY20 Earnings Revenue at Rs 1,784 Cr, Up 14%; EBITDA at Rs 480 Cr, Up 18%; Net Profit (before exceptional item) at Rs 225 Cr, Up 6%

  • Posted by: Biocon Biologics

Kiran Mazumdar-Shaw Honoured with Order of Australia, Australia’s Highest Civilian Honour

  • Posted by: Biocon Biologics
Share
buy twitter followers - omegle - matadorbet güncel adres - onwin - onwin güncel adres